Momesone

Mometasone furoate.

White to off-white, smooth and homogenous cream.
Each gram of cream contains Mometasone furoate 1 mg.

Pharmacology: Pharmacodynamics: Mometasone furoate, a synthetic corticosteroid, exhibits anti-inflammatory, antipruritic and vasoconstrictor properties. Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates.
Pharmacokinetics: The amount of Mometasone furoate absorbed from the skin depended on the duration of exposure and the surface area which it applied. The concurrent use of occlusive dressings or application to inflamed skin may increase percutaneous absorption of Mometasone furoate. About 0.7% of the drug reportedly reached systemic circulation with normal skin. Following percutaneous penetration Mometasone furoate usually are metabolized in the liver and excreted primarily by the kidneys.

MOMESONE (CREAM 0.1%) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis.

Apply a thin film to affected skin area once daily.

Overdose and Treatment: Excessive, prolonged use of topical corticosteroids can suppress hypothalamic-pituitary-adrenal function resulting in secondary adrenal insufficiency.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.

Patient who are sensitive to Mometasone furoate, to other corticosteroids or to any component of these preparation.

For topical use only; not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae.
Systemic absorption of topical corticosteroids can produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Recovery of HPA-axis function is generally prompt and complete following discontinuance of drug.
If skin irritation occurs during topical corticosteroid therapy, the drug should be discontinued and appropriate therapy initiated.
In the presence of dermatological infection, use of the appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection is adequately controlled.
Any of the side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes of visual disturbances which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Pediatric patients may be more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature individuals because of a greater skin surface area-to-body weight ratio.
MOMESONE (CREAM 0.1%) is not for ophthalmic use. Avoid contact with eyes. When applied to the eyelids or skin near the eyes because of the risk of cataract and glaucoma.

There are no adequate and well-controlled studies in pregnant women. Mometasone furoate should be used in pregnant women and nursing mothers only if potential benefit justified the potential risk to mother, fetus or infant.

Pruritus, application site reactions, bacterial infections, folliculitis, furunculosis, acneiform eruptions, signs of skin atrophy, burning, irritation, dryness, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of skin, secondary infection, striae and miliaria.
Systemic adverse reaction, such as vision blurred, have also been reported with the use of topical corticosteroids.

Not stated.

Store below 30°C.

Topical Corticosteroids

D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

E-D